Campagna et al., 2013 - Google Patents
Sulfamoylbenzamide derivatives inhibit the assembly of hepatitis B virus nucleocapsidsCampagna et al., 2013
View PDF- Document ID
- 16128805022463573822
- Author
- Campagna M
- Liu F
- Mao R
- Mills C
- Cai D
- Guo F
- Zhao X
- Ye H
- Cuconati A
- Guo H
- Chang J
- Xu X
- Block T
- Guo J
- Publication year
- Publication venue
- Journal of virology
External Links
Snippet
Chronic hepatitis B virus (HBV) infection, a serious public health problem leading to cirrhosis and hepatocellular carcinoma, is currently treated with either pegylated alpha interferon (pegIFN-α) or one of the five nucleos (t) ide analogue viral DNA polymerase inhibitors …
- 241000700721 Hepatitis B virus 0 title abstract description 196
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriphage
- C12Q1/701—Specific hybridization probes
- C12Q1/706—Specific hybridization probes for hepatitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Campagna et al. | Sulfamoylbenzamide derivatives inhibit the assembly of hepatitis B virus nucleocapsids | |
| Hu et al. | Revisiting hepatitis B virus: challenges of curative therapies | |
| Guo et al. | HBV core protein allosteric modulators differentially alter cccDNA biosynthesis from de novo infection and intracellular amplification pathways | |
| Cai et al. | Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation | |
| Berke et al. | Capsid assembly modulators have a dual mechanism of action in primary human hepatocytes infected with hepatitis B virus | |
| Guo et al. | Regulation of hepatitis B virus replication by the phosphatidylinositol 3-kinase-akt signal transduction pathway | |
| Mani et al. | Preclinical profile of AB-423, an inhibitor of hepatitis B virus pregenomic RNA encapsidation | |
| Lam et al. | Preclinical characterization of NVR 3-778, a first-in-class capsid assembly modulator against hepatitis B virus | |
| Tacke et al. | Basal core promoter and precore mutations in the hepatitis B virus genome enhance replication efficacy of Lamivudine-resistant mutants | |
| Mao et al. | Indoleamine 2, 3-dioxygenase mediates the antiviral effect of gamma interferon against hepatitis B virus in human hepatocyte-derived cells | |
| Tang et al. | The current status and future directions of hepatitis B antiviral drug discovery | |
| Petersen et al. | Aiming for cure in HBV and HDV infection | |
| Huang et al. | Preclinical profile and characterization of the hepatitis B virus core protein inhibitor ABI-H0731 | |
| Wu et al. | Discovery and mechanistic study of benzamide derivatives that modulate hepatitis B virus capsid assembly | |
| Korolowicz et al. | Antiviral efficacy and host innate immunity associated with SB 9200 treatment in the woodchuck model of chronic hepatitis B | |
| Marion et al. | Potent efficacy of entecavir (BMS-200475) in a duck model of hepatitis B virus replication | |
| Zhou et al. | Hepatitis B virus e antigen production is dependent upon covalently closed circular (ccc) DNA in HepAD38 cell cultures and may serve as a cccDNA surrogate in antiviral screening assays | |
| Li et al. | Interferon and interferon-stimulated genes in HBV treatment | |
| Farci et al. | Current and future management of chronic hepatitis D | |
| Carroll et al. | Robust antiviral efficacy upon administration of a nucleoside analog to hepatitis C virus-infected chimpanzees | |
| Martinez et al. | Biological basis for functional cure of chronic hepatitis B | |
| Howe et al. | Molecular mechanism of a thumb domain hepatitis C virus nonnucleoside RNA-dependent RNA polymerase inhibitor | |
| Liu et al. | Host poly (A) polymerases PAPD5 and PAPD7 provide two layers of protection that ensure the integrity and stability of hepatitis B virus RNA | |
| Doo et al. | Hepatitis B virology for clinicians | |
| Liu et al. | The MOV10 helicase restricts hepatitis B virus replication by inhibiting viral reverse transcription |